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Summary 
The zona pellucida (ZP), an ovarian extracellular structure, contains three major glycoproteins: 
ZP1, ZP2, and ZP3. A ZP3 peptide contains both an autoimmune oophoritis-inducing T  cell 
epitope and a B cell epitope that induces autoantibody to ZP. This study investigates two ma- 
jor T  cell costimulation pathways in this disease model. Herein we show that blockage of gly- 
coprotein (gp)39 and CD40 interaction with gp39 monoclonal antibody (mAb) results in the 
failure  to  induce  both  autoimmune  oophoritis  and  autoantibody production.  Inhibition  of 
hgand binding to the CD28 receptor with the fusion protein, murine CTLA4-immunoglobu- 
lin (Ig), also results in failure to generate antibody to ZP and significantly reduces disease sever- 
ity and prevalence. Surprisingly, the frequencies of antigen-specific T  cells in anti-gp39 mAb- 
treated mice, CTLA4-Ig treated mice, and in mice given control hamster IgG or control fusion 
protein L6, were equivalent as determined by hmiting dilution analysis  (--~  1 : 5,000). These T 
cells, which produced comparable amounts ofinterleukin 4 and interferon ~/in vitro, were able 
to transfer oophoritis to normal recipients. When anti-gp39 mAb and CTLA4-Ig were given 
together, the effect was additive, leading to inhibition of T  cell activation as determined by in 
vitro prohferation and bruiting dilution analysis (-~1:190,000); disease  and antibody responses 
were absent in these mice. By studying these two costimulatory pathways in parallel,  we have 
shown that autoimmune disease  and autoantibody production are inhibitable by blocking ei- 
ther the gp39 or the CD28 pathway, whereas inhibition of clonal expansion of the effector T 
cell population occurs only when both pathways are blocked. 
T 
cell activation by APCs is known to require multiple 
intercellular hgand  interactions.  The precise mecha- 
nisms involved in this process are only beginning to be un- 
raveled.  Whereas  specificity  is  maintained  through  the 
TCP, complex (1), many studies have shown that engage- 
ment of this receptor alone is insufficient to drive full T cell 
activation (2-4). T cell costimulatory molecules and soluble 
factors like  IL-4 and  IFN-~/  contribute to  the  process of 
converting naive T  cells into a population of clonally ex- 
panded,  effector T  cells  (5).  The best characterized of the 
costimulatory  molecules  is  CD28  and  its  receptors  on 
APCs,  CD80  (B7.1)  and  CD86  (B7.2)  (for a  review see 
reference 6).  CD28  engagement transmits a signaling cas- 
cade different from that of the TCR, possibly involving PI 
3-kinase activity (6). A number of  in vitro studies have sug- 
gested that blockage of this important pathway results  in T 
cell anergy (7-9).  In  CD28  knockout mice, normal thy- 
mocyte development occurs but peripheral T cell prolifera- 
tive responses  to  the  mitogen  Con A  are  impaired  (10). 
Humoral immune responses in these knockout mice were 
also impaired with much reduced IgG production as com- 
pared to control animals (10). 
CTLA-4 is a marker of activated T  cells that was origi- 
nally identified by screening a murine cytolytic T cell cDNA 
library (11).  CTLA-4 can bind the same receptor as CD28 
but does so with 20-fold higher affinity (12).  The function 
of CTLA-4 is unclear but recent work by Walunas  et al. 
(13)  has suggested a potential role for CTLA-4 as a nega- 
tive regulator of T  cell activation. The binding of CTLA-4 
to CD80 was first demonstrated through the use of a solu- 
ble fusion protein consisting of the extracellular domain of 
CTLA-4 and the Fc portion of a human IgG1  (12). Use of 
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ation of aUoreactive cells  (14), preventing xenograft rejec- 
tion (15) and prolonging allograft rejection (16). 
A  second costimulatory pathway is  regulated by glyco- 
protein (gp)139  (CD40L, T-BAM), a type II membrane pro- 
tein  expressed  on  activated  T  cells.  The  gp39  receptor, 
CD40, is expressed on B  cells and other APCs and is criti- 
cal for the  maturation  and differentiation  of B  cells in re- 
sponse to thymus-dependent antigens  (17).  Mice in which 
the  gp39 molecule has been disrupted  exhibit  a  decreased 
IgM  response  to  thymus-dependent  antigens  and  fail  to 
produce  germinal  centers,  suggesting  an  inability  to  de- 
velop memory B cell responses (18, 19). The importance of 
this pathway in normal human immune function is under- 
scored  by patients  with  hyper-IgM syndrome  that  results 
from a  mutated  gp39  molecule  (20).  These  patients  have 
normal  or elevated  concentrations  of polyclonal IgM and 
undetectable  or markedly reduced levels  of IgA, IgE, and 
IgG. Several studies have shown that inhibition of the gp39 
pathway  results  in  autoimmune  disease  prevention.  A1- 
lospecific CTL responses  and anti-DNA autoantibodies in 
graft-vs.-host disease were prevented by the in vivo admin- 
istration ofanti-gp39 mAb (21). Collagen-induced arthritis 
was similarly blocked by the in vivo administration ofanti- 
gp39 mAb  (22).  Recently,  Mohan et al.  (23)  have shown 
that anti-gp39 mAb was able to suppress the development 
of murine lupus nephritis and delay the onset of spontane- 
ous autoantibody formation in lupus-prone mice. 
In this study we have examined the contributions of the 
CD28 and gp39 costimulatory pathways in the generation of 
autoreactive T  cells and autoantibody production in a mu- 
rine model ofautoimmune oophoritis. CTLA4-Ig was used 
to dissect the involvement of the  CD28 pathway whereas 
anti-gp39  mAb  was  used  to  examine  the  contribution  of 
the gp39 pathway. Previous studies have reported the effi- 
cacy of these reagents in inhibiting their respective costim- 
ulatory  pathways  (14-16,  21-23).  We  now  demonstrate 
that inhibition  of either pathway is not sufficient to block 
clonal expansion  of the antigen-specific T  cell population, 
yet blockage of both pathways results in failure ofT cells to 
clonally expand.  In contrast,  inhibition  of either  pathway 
alone blocks T  cell effector function, including disease in- 
duction and T  cell help. This study therefore provides new 
insight into the relative contribution of the CD28 and gp39 
costimulatory  pathways  in  T  cell  activation  and  autoim- 
mune disease pathogenesis, and suggests an important func- 
tion for the  gp39 pathway in T  cell activation  and  clonal 
expression. 
Materials and Methods 
Mice.  (C57BL/6  ￿  A/J)  F1  (B6AF1) female  mice,  obtained 
from the Jackson Laboratory (Bar Harbor, ME) were used rang- 
ing in age from 6 to 9 wk. 
1Abbreviations used in this paper: gp, glycoprotein; IF, irrtmunofluorescence; 
ZP, zona pellucida. 
Antibodies  and Reagents.  The hamster anti-gp39 mAb, MP,-1, 
and murine  CTLA4-Ig and mAb L6 have been previously de- 
scribed  (17, 24). Control hamster IgG was purchased from Sigma 
Chemical Co.  (St. Louis,  MO).  HPLC-purified anti-gp39 mAb 
or hamster IgG was administered  (250 lig/injection, i.p.) on days 
0, 4, 8, and 12 after immunization. CTLA4-Ig (200 ~,g/injection) 
was administered  on days 0, 2, 4, and 10 after immunization. L6 
is a control mouse IgG2a mAb against a human carcinoma antigen. 
Histology and Immunohistochemistry.  Ovaries were fixed in Boum's 
solution and embedded in paraffin.  Approximately 50 serial step 
sections  per ovary, 5 Izm thick, were stained  with hematoxylin 
and eosin.  Histopathology of oophoritis was evaluated  as coded 
specimens,  with severity  graded from 1 to 4:  l,  focal inflamma- 
tion in interstitial  space; 2 and 3, increasing  multifocal  inflamma- 
tion and/or granuloma between and within ovarian  follicles; and 
4, loss of ovarian follicles and ovarian atrophy. 
Peptide Synthesis  and Purification.  Zona  pellucida  (ZP)3(330- 
342)  and  ZP3(330-340)  were  synthesized  with  an  automated 
peptide  synthesizer  (model  AMS422; Gilson Medical  Electronics, 
Inc.,  Middleton,  WI)  using fluorenyl-methoxycarbonyl (Fmoc) 
chemistry.  Peptides  were  cleaved  from  resins  by  using  TFA/ 
ethandithiol/thioanisole/anisole  at a ratio  of 90 : 3 : 5 : 2 (vol/vol). 
Peptides  were purified by HPLC on a C18 reverse phase column 
(Waters, Milford, MA). All peptides exceeded 95% purity. ZP3(330- 
342)  and  ZP3(330-340)  exhibit  similar  immunogenicity  and 
oophoritogenicity and were used interchangeably in this study. 
Immunization.  Peptides  dissolved in milli-Q water and steril- 
ized by ultrafiltration  were emulsified in an equal volume of CFA 
(Sigma  Chemical Co.).  Mice received 0.1  ml  (50 nmol)  of the 
mixture in one footpad and at the base of the tail. Animals were 
killed  14 d later and serum, lymph nodes,  and ovaries were col- 
lected. 
Detection  of Antibody  to  ZP3 Peptides or the  ZP by  Solid  Phase 
ELISA.  Each well of a 96-well flat bottom plate (Coming Glass 
Inc., Corning, NY)  was  coated with  100  ILl of a  10  ~M  ZP3 
peptide solution overnight and blocked with 3% BSA, fraction V 
(Sigma Chemical Co.) in PBS the following day.  Sera were di- 
luted and added to the wells in duplicate.  After 60 min at 20~ 
the plates were washed and further incubated with goat anti-mouse 
IgG antibody conjugated with peroxidase  (Southern Biotechnol- 
ogy Associates, Birmingham, AL) (1 : 2,500)  for 40 rain at 20~ 
After the plates were washed, a substrate mixture of O-phenylene- 
diamine  and  hydrogen  peroxide  (Sigma  Chemical  Co.)  was 
added.  Color intensity  of the mixture was deterufined at 490 nm 
on an ELISA reader (Molecular Devices, Corp., Menlo Park, CA). 
Immunofluorescence.  Ovaries were snapfrozen in liquid  nitro- 
gen and embedded in OCT compound, and 5-1*m-thick sections 
were cut in a cryostat. After the sections were fixed in 90% etha- 
nol for 15 rain,  they were rinsed in PBS for direct or indirect im- 
munofluorescence (IF). For indirect IF, the normal mouse ovarian 
sections  were  incubated with  serum diluted  in  PBS  containing 
3%  BSA for 30  rain.  After rinsing  in  PBS,  the  sections  were 
stained with FITC-conjugated goat antibody to mouse IgG or to 
mouse IgM (Cappel  Inc., Malvern, PA). Sections  were mounted 
in glycerol with 10% PBS. As a standard,  a group of slides stained 
by twofold dilutions  of  a pooled antiserum to ZP3(330-342) were 
studied in parallel. For direct IF, the sections were incubated with 
FITC-conjugated goat anti-mouse IgG antibody. 
Limiting Dilution Analysis.  Lymph node cells were seeded into 
96-well, round-bottomed microtiter plates at decreasing  concen- 
trations  from 3  ￿  104 to  117  cells/well,  in doubhng dilutions. 
The  cells were  seeded in  200  t*1 of DME  supplemented  with 
2-ME  (5  ￿  10 -5 M),  r-glutamine  (2 raM),  penicillin  (100  U/ 
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ated splenocytes (2,500 tad) were added as feeder cells (10 -s cells/ 
well).  Cultures  were  maintained  in the  absence  or presence  (20 
~M)  of antigen,  Con A  (3  ~g/ml), or irradiated feeder cells. 24 
wells were seeded at each cell concentration:  18 with antigen,  3 
with Con A, and 3 without antigen. Plates were incubated for 5 d 
in 5% CO2 at which time  100  ILl of supematant  was transferred 
into a 96-well flat-bottomed plate. 50 HT-2 indicator cells were 
then added and allowed to incubate for an additional 3 d at which 
time 10 U  of recombinant human IL-2 (a kind ~  from M. Gately, 
Hoffmann La Roche, Nutley, NJ) was added to each well. Cul- 
tures were incubated for an additional 3 d. Uptake of 3[H]thymi- 
dine was measured in the last 18 h  of culture. A positive well was 
scored by thymidine uptake exceeding the mean plus 2 SD of the 
control  wells.  Percent  negative  wells  were  plotted  against  cell 
concentration on a semilog plot. The cell number corresponding 
to 37% negative wells was considered to represent the frequency 
of lymph node cells responding to the antigen. 
T  Cell Proliferation Assay.  Lymph  node  cells  from  peptide- 
immunized mice were stimulated in vitro with varying concen- 
trations of peptide in 200  I~l complete medium in a 96-well flat- 
bottomed  plate.  The  cells were  allowed to  incubate  for 4  d  at 
37~  in 5% CO2 and air.  0.5  I~Ci of [3H]thymidine was  added 
the final day of culture,  and cell-associated radioactivity was de- 
termined in a beta counter.  Data were expressed as delta counts 
per minute  (dicpm; cpm in T  cells cultured with antigenic pep- 
tide -  cpm in T  cells cultured without antigenic peptide). 
Cytokine  Quantitation.  Lymph node cells from peptide-immu- 
nized mice were bulk stimulated in vitro with peptide for 7  d  at 
3  X  10  s cells/ml. After the 7-d incubation,  106 cells were added 
to each well of a 24-well plate coated with 0.5 btg anti-CD3 anti- 
body  (Accurate Chemical &  Scientific Corp.,  Westbury,  NY)  at 
4~  overnight. Supernatants  were collected 2  d later and used to 
stimulate indicator cell lines. IFN-~/was detected using the mac- 
rophage  cell line RAW  264  which produces  nitrite in the pres- 
ence of IFN-~ and LPS (25).  IL-4 was detected using the IL-4-- 
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Figure  1.  Serum antibody  levels are markedly  decreased  in mice re- 
ceiving anti-gp39  mAb  and/or  CTLA4-Ig.  Sera  were  collected  from 
mice 14 d after peptide  immunization from treated  control hamster  IgG 
(Vl), control L6 (~7), anti-gp39  mAb (/i), CTLA4-Ig (O), and combined 
anti-gp39  mAb plus  CTLA4-Ig (,)  animals. Standard  ELISA  data  are 
presented as optical density vs. reciprocal dilution  ofsera. A representative 
of five independent  experiments  is  shown  with  four mice per group. 
Note  that  the  CTLA4-lg-treated  group  and  combined  gp39  plus 
CTLA4-1g-treated groups  (hidden)  elicited  no  detectable  antibody  re- 
sponse. 
dependent cell line CT.4S (a kind gift from Dr. William Paul, Na- 
tional  Institutes  of Health,  Bethesda,  MD).  Cytokine  amounts 
were  standardized  against  recombinant  IFN-~/ and  IL-4 in  each 
bioassay (1K&D Systems, Inc., Minneapolis, MN). 
Adoptive  Transfer of Autoimmune Oophoritis.  Cell donors  were 
immunized with peptide in CFA, with or without CTLA4-Ig or 
anti-gp39  mAb  treatment  regimens.  Regional lymph node  cells 
obtained 14 d later were stimulated in vitro with 30 mM peptide 
for 4 d; viable T  cells obtained on Ficoll-Hypaque gradients were 
injected, intraperitoneally into normal syngeneic recipients at  107 
cells per mouse. Ovarian pathology was determined histologically 
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Figmre 2.  IgG bound to the ZP is de- 
tected by direct IF in ovaries ofpeptide- 
immunized  mice  receiving control  L6 
(A),  but  not  in  ovaries  of  peptide- 
immunized  mice  receiving CTLA4-Ig 
(~. xloo. Table  1.  Inhibition of Autoimmune Oophoritis by Blockage of the 
CD28/B7 and/or gp39/CD40  Costimulatory Pathways 
Oophoritis 
Treatment  Incidence  1  2  3  4 
CTLA4-1g  5/13  2  3  0  0 
L6 or PBS  17/18  3  4  10  0 
Anti-gp39  1/19  0  1  0  0 
Hamster IgG or PBS  24/28  7  8  9  0 
CTLA4-Ig +  anti-gp39  0/9  0  0  0  0 
L6 +  hamster IgG  9/9  1  4  4  0 
Peptide-immunized mice were treated with control reagents, CTLA4- 
Ig, anti-gp39 antibody, or both CTLA4-Ig and anti-gp39 antibody. 
Ovaries were harvested 14 d after immunization and disease was scored 
on a scale from 1 to 4 as outlined in Materials and Methods. 
14 d later. 
Statistical Analysis.  A  chi-squared analysis was used to deter- 
mine  the  significance  of difference  in  disease  incidence  among 
experimental  groups. 
Results 
The Effect  of Costimulatory  Molecule  Inhibition  on Autoanti- 
body Production.  IgG  autoantibody  production  in  immu- 
nized mice treated with  anti-gp39 mAb,  murine  CTLA4- 
Ig, or anti-gp39 mAb plus CTLA4-Ig was assessed (Fig.  1). 
Mice that received control reagents  (PBS,  L6,  hamster Ig) 
had significantly higher titers  of antipeptide  antibody at all 
dilutions  tested  compared  with  mice  receiving  anti-gp39 
mAb, CTLA4-Ig, or both reagents.  Only at the lowest di- 
lution  of sera were  any antipeptide  antibodies  detected in 
the anti-gp39 mAb-treated group. Both the CTLA4-Ig and 
combined anti-gp39  mAb plus  CTLA4-Ig group failed to 
elicit  a  detectable  autoantibody.  Similar  results  were  ob- 
tained for IgM autoantibody and antibodies detected by in- 
direct IF (data not shown). 
Direct  IF  of antibody bound  to  ZP  in  vivo  revealed  a 
pattern  of responsiveness  similar  to  the  ELISA  antibody 
finding.  Those  immunized  mice  that  received  control re- 
agents had intense staining of the ZP, whereas mice treated 
with anti-gp39 mAb,  CTLA4-Ig, or both reagents had no 
detectable zona-bound IgG (Fig. 2). 
Effect  of Costimulatory  Molecule  Inhibition  on  Ovarian  Pa- 
thology.  2 wk after immunization with an oophoritogenic 
peptide,  mice were killed and the ovaries collected.  Ovar- 
ian  histopathology from control and  treated  animals  were 
scored  from  1  to  4.  Mice  that  received  control  reagents 
(PBS, L6, hamster Ig, L6 plus hamster Ig) had a high inci- 
dence and severity of disease (Table 1). Those mice that re- 
ceived anti-gp39 mAb had virtually no disease with only 1 
mouse in 19 developing low grade inflammation after 14 d 
(Fig. 3). Mice were also studied for disease induction up to 
40  d  and  they  remained  free  of any  ovarian  pathology. 
Figure 3.  Ovarian  inflammation affecting  atretic follicles (arrowheads,  A) is detected in peptide-immunized mice receiving control hamster lgG, but not 
in mice receiving  anti-gp39 mAb (/3). (Arrows,  t3) Normal atretic follicles free of  inflammation (hematoxylin  and eosin. X200). 
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agent also  resulted in  reduction of disease.  Although 5  of 
13 mice  developed oophoritis,  the  disease  was  uniformly 
mild  and  of low  incidence  compared to  control  animals 
(p <0.005).  When both  costimulatory pathways were in- 
hibited, none of the mice developed disease. 
Thus,  inhibition  of CD28  and/or  gp39  costimulatory 
pathways resulted in the reduction of disease  incidence and 
severity and  inhibition  of IgG  autoantibody  production. 
We next investigated whether disease and antibody inhibi- 
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Figure 4.  Mice receiving both anti-gp39 mAb and CTLA4-1g have no 
in vitro proliferative response to the mununizing pept~de.  Draining lymph 
node  cells were  collected  from  mice  14  d  at~er  peptide  immunization 
from (A)  anti-gp39 mAb and hamster lgG,  (B)  CTLA4-1g and L6, and 
(Q  combined  anti-gp39  mAb/CTLA4-1g and  hamster IgG/L6  treated 
groups. (Open symbols)  Control animals; (filled symbols)  experimental ani- 
mals. Data are presented as Acpm vs. concentration of stimulating pep- 
tide.  Results of one of three  independent experiments are shown with 
each line representing the response of a single mouse and three mice con- 
mined within each group. 
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tion  were  associated  with  a  reduction  of effector T  cell 
generation. 
Effect of Costirnulatory Molecule Inhibition on In  Vitro Prolif- 
eration of Lymph Node Cells.  Lymph node cells from con- 
trol and treated animals were stimulated in vitro with vari- 
ous concentrations of the immunizing peptide (Fig.  4). At 
all  of the  peptide  concentrations examined,  no  statistical 
difference in the proliferative capacity was noted between 
anti-gp39 mAb-treated and control animals (Fig. 4 A). Sim- 
ilarly, no statistical difference was noted between the CTLA4- 
lg-treated group and control animals (Fig. 4 B). However, 
when  both  the  gp39  and  CD28  costimulatory pathways 
were  blocked,  proliferation was  not  seen  at  any  peptide 
concentration tested (Fig.  4  C). These results suggest that 
blockage of either the gp39 or CD28  costimulatory path- 
way does not render the antigen-specific T  cells unrespon- 
sive  to  a  second in  vitro challenge with  the  immunizing 
peptide. 
Frequency of Responding Antigen-specific T  Cells Determined 
by Limiting Dilution Analysis.  The frequency of ZP3 pep- 
tide-specific responding T  cells was determined in mice of 
all treatment groups 2  wk  after immunization.  Frequency 
analysis  of the antigen-specific T  cell population failed to 
detect a significant difference between the anti-gp39 mAb- 
treated  and  control  animals  (Fig.  5  A).  A  calculated  fre- 
quency of 1 in 4,971 was determined for the anti-gp39 mAb- 
treated  animals  whereas  the  control  animals  displayed  a 
frequency of 1 in 6,096 cells being antigen specific. Like- 
wise, clonal expansion of antigen-specific T  cells occurred 
in CTLA4-lg-treated animals at the same frequency as that 
seen in control animals (1  in 5,914 vs.  1 in 5,849,  respec- 
tively; Fig. 5 B). 
When both the gp39 and CD28 pathways were blocked, 
T  cell frequency analysis  revealed a  marked reduction in 
the number of responding antigen-specific T  cells as com- 
pared to control animals (1  in 184,894 vs. 1 in 5,551) (Fig. 
5 C). Moreover, the gross size of the regional lymph nodes 
in  control animals  and  those  animals  that  received either 
anti-gp39 mAb or CTLA4-Ig alone were enlarged, whereas 
lymph nodes from mice that received both anti-gp39 mAb 
and CTLA4-Ig were similar to those ofunimmunized mice 
(data  not shown).  These results suggest that clonal expan- 
sion ofautoreactive T  cells does not depend exclusively on 
a single pathway, but rather, depends on multiple comple- 
mentary pathways. 
h  is  interesting that  mice  treated with  anti-gp39  mAb 
alone or with CTLA4-Ig alone had proliferative T  cell re- 
sponses to the immunizing peptide without oophoritis or 
anti-ZP antibody production. We next determined whether 
the cytokines produced by these T  cells had altered in the 
presence  of these  inhibitors.  In  addition,  we  determined 
the  ability of the  clonally expanded T  cells  to adoptively 
transfer oophoritis to normal recipients. 
Cytokine  Production by  CIonally Expanded  T  Cells in Mice 
Treated with CTLA4-Ig or Anti-gp39 mAb.  When  activated 
in  vitro with  the  immunizing peptide,  T  cells from mice 
treated with CTLA4-Ig or anti-gp39 mAb produced amounts 
of IFN-~/ and  IL-4 comparable with  control mice  (Table A  1 
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Table 2.  Inhibition  of the CD28/B7 or gp39/CD40 
Costimulatory Pathways Does not Alter the Cytokine Phenotype 
of Lymph Node Cells 
Cytokine 
Treatment  IFN-3'  IL-4 
U  pg 
CTLA4-Ig  104 +  34  29 •  27 
Anti-gp39  106 •  27  42 •  50 
Control  106 +  70  58 •  51 
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Figure 5.  Mice  receiving both anti-gp39 mAb and CTLA4-1g have a 
marked reduction in the  clonal expansion of antigen-specific T  cells. 
Draining lymph node cells were collected 14 d after peptide immuniza- 
tion from (A) anti-gp39 mAb and hamster IgG, (B) CTLA4-Ig and L6, 
(C)  combined anti-gp39 mAb/CTLA4-Ig and hamster IgG/L6 treated 
groups. (Open symbols) Control animals; (filled  symbols) experimental ani- 
mals. Data are presented as percent negative wells vs. number of  cells per 
well. Results of one of  three independent experiments are shown. 
2). Therefore, a change in cytokine profile or T  helper cell 
subset is not associated with the reduction in the incidence 
of autoimmune oophoritis in the treated groups. 
Adoptive Transfer of Autoimmune  Oophoritis by Lymph Node 
Cells  from Peptide-immunized Mice Treated with CTLA 4-Ig or 
Anti-gp39 mAb.  Lymph  node  cells  from peptide-immu- 
nized  mice  transferred  comparable  incidence  and  severity 
of oophoritis to normal recipients regardless of whether the 
donors had received CTLA4-Ig (3/4), anti-gp39 mAb (6/8), 
or control reagents (5/7) (Fig. 6). Whereas clonally expanded 
T  cells  do  not  elicit  significant  oophoritis  in  the  donors, 
Peptide-immunized mice were treated with control reagents, CTLA4- 
Ig, or anti-gp39 Ab. Lymph node cells were harvested 14 d after immu- 
nization and cytokine production assessed as outhned in Materials and 
Methods. The results from six mice per group are shown. 
these  cells,  upon activation in vitro,  are pathogenic.  Also, 
Con  A-stimulated  spleen  cells  from animals  treated  with 
both CTLA4-Ig and  anti-gp39 mAb failed to transfer dis- 
ease  (0/6).  Lymph  node  cells  from  animals  treated  with 
both  CTLA4-Ig  and  anti-gp39  mAb  failed  to  generate 
enough cells for adoptive transfer. 
Discussion 
Experimental murine autoimmune oophoritis is induced 
by immunization with  a  10-  or  11-mer synthetic  peptide 
corresponding  to  mouse  ZP3  proteins  330-341  and  330- 
342 (26-28). The ovarian inflammation is transferrable by a 
CD4 + clone of the Thl  phenotype (27).  Animals injected 
with  the  ZP3  peptide  also  develop  autoantibodies  to  the 
ZP, and the response is driven, in part, by endogenous ZP 
antigens (26).  However, induction of high ZP antibody ti- 
ters,  without  concomitant T  cell response  to the  peptide, 
does not cause  ovarian pathology (29).  Thus,  like  experi- 
mental  autoimmune  encephalomyelitis,  oophoritis  is  pri- 
marily  an  inflammatory  CD4 +  T  cell-mediated  autoim- 
mune disease.  Based on this model, we have evaluated,  in 
parallel,  the participation of the gp39 and the CD28 path- 
ways in autoantibody induction, ovarian disease, and clonal 
expansion of ZP3 peptide-specific T  cells. 
Our results  indicate  that  blockage  of each  of the  path- 
ways was associated with inhibition or significant reduction 
in  the  prevalence  and  severity  of ovarian  pathology.  The 
ZP  antibody response  was  simultaneously  ablated.  Some- 
what surprisingly,  these  changes were  not associated with 
reduction in clonal expansion  of the  ZP3 peptide-specific 
T  cells as measured by limiting dilution analysis. Moreover, 
T  cells from mice treated with anti-gp39 mAb or CTLA4-Ig 
produced amounts of IFN-y and IL-4 similar to that of un- 
treated mice, and they were able to transfer severe oophoritis 
to normal recipients. 
In contrast,  when  both  pathways were  blocked,  T  cell 
responses, ovarian pathology, and antibody induction were 
806  Costimulatory Molecules in Autoimmunity Figure 6.  Adoptive  transfer  of in vitro-stimulated  lymph node cells  from peptide-immunized  and anti-gp39 mAb (A) or CTLA4-1g  (B) treated  mice 
results in ovarian  pathology. (A) The focus  ofgranulomatous  inflammation  is outlined  by thick arrows; long arrows point to a multinuclear  giant cell. (B) 
Arrows point to an inflammed  atretic follicle  that contains lymphocytes  and macrophages. (hematoxylin  and eosin, ￿ 
completely inhibited.  This  state  of unresponsiveness  was 
temporary  and  showed  no  evidence  of long-term  toler- 
ance.  Thus  1  mo  later,  when  CTLA4-Ig  and  anti-gp39 
mAb levels had declined, these mice were fully capable of 
developing both  T  cell  responsiveness  and  autoimmune 
oophoritis when rechallenged with  ZP3  peptide  in  CFA 
(data not shown). 
The interaction of gp39 and CD40 is critical in the for- 
marion  of isotype-switched antibody as  well  as  germinal 
center formation within  secondary lymphoid tissues  (17- 
19).  In vivo administration of anti-gp39 mAb dramatically 
reduced both primary and secondary humoral immune re- 
sponses without altering responses to T-independent anti- 
gens (30).  Likewise, blockage of the CD28 pathway inhib- 
its  autoantibody  production.  Milich  et  al.  (24)  using  a 
hepatitis B e-Ag transgenic system found CTLA4-Ig effec- 
tive in suppressing autoanribody production. Murine lupus, 
a  disease  mediated via autoanribody production,  was  also 
effectively treated with CTLA4-Ig (31). Thus, it is not sur- 
prising that either anti-gp39 mAb or CTLA4-Ig also inhib- 
ited antibody production in our model of autoimmunity, 
reinforcing the potential application of anti-gp39 mAb and 
CTLA4-Ig in the treatment of antibody-mediated autoim- 
mune diseases. 
Blockage of either the gp39  or CD28  pathway had no 
effect on T  cell clonal expansion, whereas inhibition of  both 
significantly reduced T  cell expansion. Thus, either of the 
pathways can mediate T  cell clonal expansion; when one is 
blocked, the other remains operative, and vice versa. The 
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results also imply that other costimulatory pathways consid- 
ered important in T  cell activation do not always compen- 
sate  for the CD28  and gp39 pathways in vivo. In this re- 
gard,  several  receptor/ligand  pairs  have  been  shown  to 
interact and costimulate T  cell activation in vitro. Intercel- 
lular adhesion molecule 1  (ICAM-1)  and vascular cell ad- 
hesion molecule  1  (VCAM-1)  can  efficiently costimulate 
the prohferation of resting T  cells while poorly stimulating 
antigen-specific T  cells (32). Also, CD80/CD86 and LFA-3 
have been implicated in the preferential stimulation of anti- 
gen-specific T  cells. Finally, these and other studies suggest 
that the requirements for T  cell activation may change with 
the differential stage of the responding T  cell (33). 
The result of normal clonal expansion of ZP3-specific T 
cells in the presence of CTLA4-Ig is also unexpected given 
the importance of  the CD28 costimulatory pathway for IL-2 
production  (34,  35).  However,  similar  results  were  re- 
ported  by  Ronchese  et  al.  (36),  in  that  mCTLA4-Hgl 
transgenic mice were found to have enhanced levels of an- 
tigen-specific T  cells after secondary or tertiary immuniza- 
tion with KLH. Together, these two studies suggest that al- 
ternative  surface  receptors  may  be  available  for  clonal 
expansion and IL-2 production. On the other hand, recent 
work  by Kearney et  al.  (37)  has  suggested  that  antigen- 
dependent  clonal  expansion  is  solely  contingent  upon 
CD28 costimulation. They found that blockage of CD28/ 
B7 interaction with CTLA4-Ig results in failure to clonally 
expand a population of adoptively transferred transgenic T 
cells  to  a  foreign ovalbumin peptide.  The  reason for the discrepancy between their finding of inhibition of clonal 
expansion and our lack of  such a finding is unclear but may 
be due to differences in immunogenicity between the for- 
eign ovalbumin peptide and a self-peptide that may have 
primed the immune system previously. 
Blockage of either the gp39 or the CD28 pathway did 
not inhibit clonal expansion ofZP3-specific T cells, yet these 
T  cells failed to cause significant ovarian disease.  Thus co- 
operation between the two pathways is required in func- 
tional acquisition of clonally expanded T  cells.  Indeed, it 
has  been postulated  that  these pathways  may operate se- 
quentiaUy for clonally expanded T  cells to differentiate into 
functionally active effector T  cells (38). The fact that T  cell 
clonal  expansion  occurs  without  concomitant functional 
acquisition also supports the in vitro finding that T  cell ac- 
tivation occurs in multiple discrete steps each of which re- 
quires distinct signals (39). 
Why the clonally expanded T  cells  should fail to elicit 
oophoritis is an important question. They may lack homing 
molecules or additional downstream  costimulatory mole- 
cules.  Failure  of these cells  to produce appropriate  cyto- 
kines  for induction  of ovarian  pathology is  a  possibility 
under  current  investigation.  Alternatively,  the  circulating 
anti-gp39 mAb may block T cell recognition of target anti- 
gens in  the  ovary. This is,  however,  unlikely since  anti- 
gp39 mAb does not inhibit oophoritis induced by adoptive 
transfer of a pathogenic ZP3-specific T  cell line (our un- 
published data).  Finally, the clonally expanded T  cells are 
not anergic as they responded to the stimulating peptide in 
vitro without exogenous IL-2. Indeed, adoptive transfer of 
these in vitro-stimulated cells into naive hosts resulted in 
ovarian pathology  (Fig.  6).  Thus,  the  functional state  of 
these autoreactive T  cells would appear to be contingent in 
some  way  on  the  gp39/CD40  interaction.  Whether this 
gp39 help is provided indirectly via soluble mediators from 
the APC or through an as yet unidentified signaling struc- 
ture associated with the gp39 molecule is currently being 
investigated. 
A role for gp39 in costimulation of CD4 + T  cells is also 
supported by a recent study (40). These investigators found 
that of a panel ofP815 transfectants, CD40-P815 preferen- 
tiaUy costimulated in vitro proliferation of resting T  cells in 
the  presence  of anti-CD3  mAb  whereas  CD56,  ICAM, 
VCAM,  CD31,  CD72,  and FAS transfected P815 cells all 
failed to elicit proliferation. It is interesting that hyper-IgM 
syndrome patients are particularly susceptible to opportu- 
nistic infections that involve the T  cell effector arm of the 
immune  system  (41).  Alderson  et  al.  (42)  have  demon- 
strated that in human monocytes, gp39/CD40  interaction 
promotes the production of TNF-r  and IL-6 in the mono- 
cyte population.  Taken  together,  there is  mounting evi- 
dence for direct or indirect signaling to the T  cell via the 
gp39 molecule. 
In the context of immunologic tolerance, one potential 
mechanism is T  cell ignorance, this describes the presence 
of self-reactive T  cells being oblivious or ignorant to nor- 
mal, accessible  self-peptides (for a review see reference 43). 
Our findings suggest that clonally expanded, self-reactive T 
cells can still remain ignorant. 
When mice were treated with both CTLA4-Ig and anti- 
gp39 antibody, neither clonal expansion nor oophoritis was 
manifested. Moreover, their splenic T  cells, activated with 
Con A, also  did not transfer oophoritis to normal recipi- 
ents. This is not surprising in view of the low frequency of 
ZP3-specific T  cells  detected in this group  of animals.  A 
more challenging issue  is whether tolerance or some sup- 
pression mechanism has been imposed by ZP3 immuniza- 
tion in animals with blockage of both costimulatory path- 
ways.  Our  preliminary  results  do  not  support  tolerance 
induction.  At  5  wk  after  initial  immunization,  when 
CTLA4-Ig  and  anti-gp39  antibody  should  have  disap- 
peared from the mice, two of four animals developed se- 
vere  oophoritis  upon  rechallenge  with  ZP3  peptide  in 
CFA. However, this point needs further investigation. 
Inhibition of the gp39 and the CD28 pathways provides 
potential  therapeutic  approaches  to  control  autoimmune 
disease and allograft rejection. It will be important to deter- 
mine whether inhibition of  these pathways also reverses au- 
toimmune oophoritis. Nevertheless, the results of this study 
suggest that inhibition of both gp39 and CD28 costimula- 
tory pathways will provide much more complete immuno- 
suppression than inhibition of either pathway alone. 
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